The incidence and survival of breast cancer (BC) vary across countries. This study aimed to determine risk factors for BC and estimate the overall survival rate in BC patients of the Golestan Cohort Study (GCS).
Methods
This case-control study was performed among participants of the GCS. Cases (N = 99) consisted of women who were diagnosed with BC and controls (n = 400) were selected out of women participating in the same cohort and had not developed any cancer during the follow-up period. Controls were frequency matched to case on both place of residency and 5-year categories of age.
Results
Considering confounding variables, logistic regression analysis manifested a reverse association between parity and BC (OR [odds ratio] = 0.87, 95% CI: 0.80-0.95, P = 0.001). In addition, we found women who had family history of any cancer (OR = 1.63, 95% CI: 1.02-2.60, P = 0.04) and long term oral contraceptive (OCP) use (≥10 years) (OR = 3.17, 95% CI: 1.27-7.95, P = 0.01) were at higher risk of BC. Of the total patients, 23 (23.2%) were died due to BC after a mean follow-up of 102.4 ± 5.31 months. Using the Kaplan-Meier analysis, the 5-year survival in these patients was 74%.
Conclusion
In the Golestan Cohort population, long term OCP use and family history of cancer were risk factors for BC, while parity was a protective factor. The 5-year survival of BC patients in the GCS is still lower relative to Europe and the United States.
oral contraceptive use breast cancer risk, parity protective factor breast cancer, family history cancer breast cancer, long-term ocp use oncology risk, contraceptive pill 10 years breast cancer, multiparity breast cancer protection, iran breast cancer incidence, golestan cohort breast cancer survival, reproductive factors breast cancer epidemiology, hormonal contraception breast cancer case-control
Cite this article
Alipour, S., omranipour, R., Malekzadeh, R., Poustchi, H., Pourshams, A., khoshnia, M., Gharavi, A., Roshandel, G., & Eslami, B. (2019). A Case-Control Study of Breast Cancer in Northeast of Iran: The Golestan Cohort Study. *Archives of Iranian medicine*, *22*(7), 355-360. https://doi.org/S1029-2977-22(07)355-0
Alipour S, omranipour R, Malekzadeh R, Poustchi H, Pourshams A, khoshnia M, et al. A Case-Control Study of Breast Cancer in Northeast of Iran: The Golestan Cohort Study. Arch Iran Med. 2019;22(7):355-360. doi:S1029-2977-22(07)355-0
Alipour, Sadaf, et al. "A Case-Control Study of Breast Cancer in Northeast of Iran: The Golestan Cohort Study." *Archives of Iranian medicine*, vol. 22, no. 7, 2019, pp. 355-360.
Yonis H et al., 2025
Open Access
BMJ (Clinical Research Ed.)
Objective: To evaluate the association between contemporary hormonal contraceptive use and the risk of incident ischaemic stroke and myocardial infarction.
Design: Real-world, nationwide, prospective ...
Contraception/Comparison > Side Effects > Hormonal ContraceptionContraception/Comparison > FABM vs Hormonal > Side EffectsGeneral OB/GYN > Epidemiology > Prevalence
Background: The combined hormonal contraceptive (CHC) with ethinylestradiol and progestins is the most widely used contraceptive method among young women and is used by millions worldwide. However, un...
Contraception/Comparison > Side Effects > Hormonal ContraceptionContraception/Comparison > FABM vs Hormonal > Side EffectsGeneral OB/GYN > Epidemiology > Prevalence
Huang Y et al., 2024
Open Access
Frontiers in Endocrinology
Background: Premature ovarian insufficiency/failure (POI/POF) is a significant issue for women of reproductive age. Anti-Müllerian hormone (AMH) is a potential biomarker of ovarian reserve, but its cl...
Contraception/Comparison > FABM vs Hormonal > Side EffectsContraception/Comparison > Side Effects > Hormonal ContraceptionGeneral OB/GYN > Epidemiology > Prevalence
Khoramdad M et al., 2022
Open Access
European Journal of Medical Research
Background: Identifying breast cancer risk factors is a critical component of preventative strategies for this disease. This study aims to identify modifiable and non-modifiable risk factors of breast...
General OB/GYN > Epidemiology > PrevalenceContraception/Comparison > Side Effects > Hormonal Contraception